Letter to the Editor
Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: Unfavorable risk-benefit ratio†‡§
Allergan, Inc. had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Relevant conflict of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
No abstract is available for this article.